Incidental Thyroid Nodules Found During Acute Stroke Angiography: Prevalence,Outcomes,and Suggested Management Guidelines

Materials and Methods

This was conducted based on a retrospective data collection at a single-center urban academic referral hospital’s IRB-approved registry. The data were pulled for patients admitted for acute stroke-like symptoms between January 2017 through September 2019. The researchers reviewed neck computerized tomography angiography (CTA) and magnetic resonance imaging angiography (MRA) reports for thyroid nodules. Patient demographics, medical history, clinical features, pathologic diagnosis, and follow-up were obtained from electronic medical records. Risk factors for thyroid carcinoma were recorded (childhood radiation exposure, family history of thyroid cancer, or hereditary cancer syndromes).^3,10 All radiology images and reports with incidental thyroid nodules were manually reviewed by the study team to identify suspicious imaging findings (abnormal lymph nodes, extrathyroidal extension). ¹¹ All pathologic reports were reviewed by a board-certified cytopathologist. To include only new incidental nodules, it was important to exclude patients with clinical history of thyroid nodules, palpable neck masses, and symptomatic thyroid enlargement.

Results

Patient Population

The review identified 13 563 patients who received either neck CTAs or MRAs as part of their stroke work-up between January 2017 through September 2019. Incidental thyroid nodules were found in 192 patients (prevalence 1.4%), all on CTA. Twenty-six patients (14%) subsequently died of causes unrelated to thyroid disease, preventing additional investigation. Figure 1 illustrates patient selection. Twenty-two patients (16 females, 6 males; mean age: 61 years, standard deviation ± 10 years) received subsequent sonograms. All requests for thyroid sonography included a request to perform biopsy if indicated. The characteristics of these patients are summarized in Table 1.

OPEN IN VIEWER

Figure 1.

Flow diagram for selection of patient records that were reviewed in this study.

OPEN IN VIEWER

Table 1.

Characteristics of Patients Who Received Work-Up (n = 22).

Age (mean ± SD)	61 ± 10
Sex	16 F, 6 M
Nodule size (mean ± SD, [range])	1.5 cm ± 0.6, [0.3–3]
Patients who met imaging criteria for U/S	14
Patients who met sonographic criteria for FNA	10
Follow-up	Thyroid cancer: 1 No evidence of thyroid disease: 21

Abbreviations: F: female, FNA: fine needle aspiration, M: male, U/S: ultrasound.

Pathologic Findings and Diagnostic Follow-Up

FNA results are summarized in Table 2. There were 10 benign nodules, 1 indeterminate (follicular lesion of undetermined significance), and 1 papillary thyroid carcinoma, representing an 8% rate of malignancy for sampled nodules. The patient with indeterminate results opted for close clinical surveillance. The patient with malignant results underwent hemithyroidectomy with a final diagnosis of papillary thyroid carcinoma, classic type, 2.4 cm, confined to the thyroid (clinical stage II disease). However, his course was complicated by acute ischemic stroke 9 months later, apparently unrelated to cancer. He has no evidence of malignancy at 2-year follow-up. The diagnostic follow-up for the remaining patients showed asymptomatic thyroid nodules that are unchanged or diminishing in size.

OPEN IN VIEWER

Table 2.

Cytologic Results (n = 12 nodules).

Benign	10
FLUS	1
Malignant	1
Rate of malignancy	8%

Abbreviation: FLUS: follicular lesion of undetermined significance.

Discussion

Based on a search of the literature, this study is the first to report clinical outcomes and risk of malignancy for incidental thyroid nodules noted in stroke work-up. Of 13 563 patients who had neck vascular imaging, only 192 patients had at least one incidental thyroid nodule (1.4% prevalence). Although prior studies have reported only prevalence of incidental thyroid nodules in stroke patients,^8,9 this report also describe outcomes and includes all patients who undergoing neck vascular imaging, for acute stroke symptoms. Of 22 patients who received follow-up sonogram, 10 had at least one thyroid nodule that qualified for FNA biopsy, and only one had malignancy. Thus, 95% of this cohort of patients who received an additional sonogram, for incidentally detected CTA nodules, had clinically insignificant findings. These results may further aid clinicians in initial management of this patient population.

Incidental thyroid nodules have been reported in up to 18% of CT/MRI examination of the neck, ¹¹ with CT appearing to be more sensitive. ⁸ Prevalence varies among studies: One reported 6% prevalence in stroke patients ⁸ while another reported 0.6% prevalence in trauma patients. ¹³ However, CT is not considered an appropriate diagnostic modality for thyroid disease, and concordance with dedicated thyroid sonogram is only 53%.^2,11 Discrepancies include false positive nodule identification, missed lesions of 3–5 mm slices, and artifacts produced by patient positioning. ² Prevalence in CTA, as in this study, has only been sparsely described in the literature.^8,9 It would appear that the risk of malignancy in CTA-detected nodules has not been previously reported. Nonetheless, this cohort’s malignancy rate of 8% falls within the reported range of 4–16% for nodules identified on chest and neck CT. ² Since this cohort’s rate of malignancy was calculated using only nodules that met TIRADS criteria for FNA, rate might be lower when one considers all CT-noted nodules.

Sonographic evaluation has been recommended for suspected thyroid nodules, although the 2015 American Thyroid Association guidelines acknowledge that sub-centimeter nodules generally do not need additional work-up. ¹⁰ However, clinicians may need guidance for special populations of elderly patients or those with poor health status who may not benefit from extensive interventions. In 2015, the ACR white paper reported guidelines on work-up of CT or MRI detected incidental thyroid nodules. ¹¹ If no suspicious imaging findings (extrathyroidal extension, abnormal lymphadenopathy) are noted, suggested management is as follows:

Applying ACR guidelines to these study patients would have prevented 8 unnecessary thyroid sonograms and 1 unnecessary FNA. None of these patients would have had a missed malignant nodule. This report leaves evaluation of life expectancy and severe comorbidities up to clinician interpretation. Considering this cohort of patients, with incidental nodules, 14% died of severe medical comorbidities unrelated to thyroid disease. In this population, with poor health status, these patients were recommended thorough clinical evaluation to prevent unnecessary work-up. Perhaps, future clinical consensus guidelines may be helpful for more efficient work-up, especially in cases where size is difficult to ascertain.

The only malignancy was papillary thyroid carcinoma, detected during work-up for a patient diagnosed with a transient ischemic attack. The patient was 71 at the time of cancer diagnosis and subsequently suffered acute stroke less than a year after surgical treatment. It is unclear what impact thyroid cancer treatment had to his life expectancy and quality of life, if any. Multiple studies have shown incidental thyroid carcinoma shows less aggressive features, reduced recurrence, and longer progression-free survival when compared to clinically detected thyroid carcinoma.^14,15 Papillary thyroid carcinoma, the most common incidental malignancy,^14,15 has an excellent prognosis. ¹⁶ Even untreated patients have an indolent course. Prior studies show 3 to 36% of autopsy patients have occult thyroid carcinoma with no complications in life.^1,12,17,18 Studies from multiple countries have shown small papillary carcinomas can be managed with active surveillance alone, although this practice is not widespread in the United States. ¹⁹ Remarkably, population-based research has demonstrated thyroid cancer incidence is positively correlated with density of endocrinologists ¹⁸ and elevated socio-economic status ¹⁶ and negatively correlated with percentage of uninsured patients. ²⁰ Most likely, increased access to care has led to what some have described as an “overdiagnosis” of cancer. ¹⁸ With increasing incidence and excellent long-term survival, papillary thyroid carcinoma is costly to the health care system. Based on current trends, the projected cost is expected to surpass $3.5 billion by 2030, and the greatest cost is initial diagnosis and treatment. ¹⁹ The initial cost includes sonographic evaluation, FNA biopsy, and surgery and adjuvant treatment. Reducing unnecessary testing and instead taking a more individualized and evidence-based approach would be beneficial for patients and the health care system.

Although the cost of a sonogram is minimal compared to the cost of surgery, there are still issues with indiscriminately ordering this evaluation for every incidental thyroid nodule. Even if the nodule does not meet criteria for FNA at the initial sonogram, the patient’s provider may elect to repeat sonography at an interval of 6–24 months. If a patient initially has benign cytology results, follow-up sonogram or repeat biopsy may be performed based on how concerning the imaging findings are. ¹⁰ These extra appointments and procedures may be excessive for patients with disability and limited life expectancy due to severe medical comorbidities. Up to 30% of thyroid FNA biopsies are “indeterminate.” ³ In this study, only one patient had indeterminate FNA results and opted for close clinical follow-up only. However, per current management guidelines, indeterminate nodules can receive significant additional procedures, including repeat FNA, molecular testing or even diagnostic lobectomy. ¹⁰ Even though indeterminate nodules are most often benign on final pathology,^3,19 all these additional procedures can lead to unnecessary post-surgical complications and health care costs. Just molecular testing alone costs $3000–$5000. ³ These extra procedures and tests can pose serious implications if the initial ultrasound was not medically necessary in the first place.

Therefore, it is not necessary to perform sonography on every incidental thyroid nodule. Instead, it may be prudent to follow the ACR guidelines based on CT imaging characteristics, nodule size and patient age. These guidelines help identify patients who would most benefit from further evaluation. For example, prior studies of healthy adults have shown incidental thyroid nodules in younger patients are more likely to be malignant, so follow-up sonogram of smaller nodules is advised. ¹¹ Additionally, it may be important for patients to have a thorough baseline clinical evaluation, for those undergoing acute stroke work-up, given that the significant comorbidities that could dramatically shorten life expectancy.

The strength of this study is the large number of patients receiving neck vascular imaging for an acute stroke symptom work-up. This patient population, which was generally older and included other medical comorbidities, has not been well-reported in the literature. While most studies have focused solely on the prevalence of incidental thyroid nodules, this study also evaluated pathologic results and follow-up for all the thyroid nodules noted.

This work is limited by being a single-institution study, so clinical practice at the host hospital and therefore cannot be generalized. Additionally, these methods resulted in an older study population, so the results cannot be generalized to patients of all ages. Nonetheless, the intent was to show incidental thyroid nodule outcomes in a patient population that was unlikely to benefit from significant interventions. Further research, including large, multi-institutional studies, could shed light on widespread clinical practice.

Conclusion

This study was based on the review of incidental thyroid nodules, in patients undergoing acute stroke work-up and is a population that has not been routinely evaluated. It was noted that over 90% of patients with incidental thyroid nodules did not benefit from additional interventions, including sonography and biopsy. These results would suggest a more individualized approach based on nodule size, presence or absence of imaging findings concerning for malignancy, and ruling out significant comorbidities that would shorten life expectancy more than occult thyroid carcinoma itself.